866-997-4948(US-Canada Toll Free)

Streptococcus Pneumoniae Infection - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Apr 2013

Category :

Therapeutic Area

No. of Pages : 48 Pages


Global Markets Direct’s, \'Streptococcus Pneumoniae Infection - Pipeline Review, H2 2013\', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection. 

Streptococcus Pneumoniae Infection - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Streptococcus Pneumoniae Infection.
  • A review of the Streptococcus Pneumoniae Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Streptococcus Pneumoniae Infection pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Streptococcus Pneumoniae Infection.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Streptococcus Pneumoniae Infection pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Introduction
Global Markets Direct Report Coverage
Streptococcus Pneumoniae Infection Overview
Therapeutics Development
An Overview of Pipeline Products for Streptococcus Pneumoniae Infection
Streptococcus Pneumoniae Infection Therapeutics under Development by Companies
Streptococcus Pneumoniae Infection Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Streptococcus Pneumoniae Infection Therapeutics – Products under Development by Companies
Streptococcus Pneumoniae Infection Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Streptococcus Pneumoniae Infection Therapeutics Development
GlaxoSmithKline plc
Daiichi Sankyo Company, Ltd
Paratek Pharmaceuticals, Inc.
ImmunoBiology Limited
Streptococcus Pneumoniae Infection – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
omadacycline tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pneumococcal Vaccines - Drug Profile
Product Description
Mechanism of Action
R&D Progress
avarofloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2830930-A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PnuBiovax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pneumococcal Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vi-PspA Conjugate Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Compound-2a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Streptococcus Pneumoniae Infection Therapeutics – Drug Profile Updates
Streptococcus Pneumoniae Infection Therapeutics - Dormant Products
Streptococcus Pneumoniae Infection – Product Development Milestones
Featured News & Press Releases
Feb 28, 2011: Trius Reports Positive Results From Phase I Lung Study Of Torezolid Phosphate
Oct 29, 2010: Forest Receives FDA Approval For Teflaro For Treatment Of Community-Acquired Bacterial Pneumonia And Acute Bacterial Skin And Skin Structure Infection
Jul 28, 2009: Wyeth recalls lot of Prevnar vaccine.
Oct 04, 2007: Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease.
Jul 27, 2007: Wyeth Team Recognized by White House With Prestigious National Medal of Technology for PREVNAR Vaccine.
Mar 21, 2005: Wyeth Vaccines Researchers Honored by Pharmaceutical Industry; Developers of Prevnar Receive Prestigious Discoverers Award From the Pharmaceutical Research and Manufacturers of America (PhRMA).
Sep 16, 2004: CDC Recommends Return to Full Four-Dose Series of Prevnar
Sep 01, 2004: Drug-resistant infections drop with Prevnar use.
Jul 08, 2004: Centers for Disease Control and Prevention Recommends Resumption of 3rd Dose of Prevnar; Supply of Prevnar Improving.
Feb 12, 2004: Wyeth Reaffirms Distribution Plan for Prevnar to Optimize Product Availability for Children.

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Table


Number of Products Under Development for Streptococcus Pneumoniae Infection, H1 2013
Products under Development for Streptococcus Pneumoniae Infection – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
GlaxoSmithKline plc, H1 2013
Daiichi Sankyo Company, Ltd, H1 2013
Paratek Pharmaceuticals, Inc., H1 2013
ImmunoBiology Limited, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Streptococcus Pneumoniae Infection Therapeutics – Drug Profile Updates
Streptococcus Pneumoniae Infection Therapeutics – Dormant Products

List of Chart


Number of Products under Development for Streptococcus Pneumoniae Infection, H1 2013
Products under Development for Streptococcus Pneumoniae Infection – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Late Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *